This book provides an up-to-date evaluation of clinical aspects of newly available "long-circulating liposome" formulations. Based on results from numerous clinical studies, the book describes the fundamentals of this new technology, discusses how it may influence the pharmacology of existing well-known agents reformulated in this manner, and elaborates on future expectations. It provides the practicing clinician - in particular, oncologists and critical care infectious disease physicians - with the tools needed to use these new formulations towards the best outcome for the patient.

1. Long Circulating Liposome Therapeutics: From Concept to Clinical Reality

2. Oncologic Agents in Sterically Stabilized Liposomes: Basic Considerations
3. Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations
4. Long Circulating Liposome-Encapsulated Tumor Necrosis Factor in the Treatment of Solid Tumors
5. Therapy of Human Carcinoma Xenografts with Doxorubicin Encapsulated in Sterically Stabilized Liposomes (DOXIL®): Efficacy and Safety Studies
6. Design and Development of Long Circulating Liposomal Daunorubicin for In Vivo Targeting of Solid Tumors: DaunoXome®
7. Enhancement of Doxorubicin by Encapsulation in Long circulating Thermosensitive Liposomes Combined with Local Hyperthermia
8. Liposomal Localization and Chemotherapy for AIDS-Related Kaposi's Sarcoma
9. Pegylated-Liposomal Doxorubicin (Doxil®) in the Treatment of AIDS-Related Kaposi's Sarcoma
10. DaunoXome® (Liposomal Daunorubicin) for First-Line Treatment of Advanced, HIV-Related Kaposi's Sarcoma
11. Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors
12. Antibacterial Therapy with Sterically Stabilized Liposome Formulations
13. AmBisome®: Long Circulating Liposomal Formulation of Amphotericin B
14. Steric Stabilization of Liposomes Containing Amphotericin B: A Future Direction in Antifungal Therapy?
15. Clinical and Preclinical Studies with Low-Clearance Liposomal Amikacin (MiKasome®)
16. Sterically Stabilized Liposomes to Image Infection and Inflammation
17. Long Circulating Liposomes for Diagnostic Imaging
18. Tumor Imaging with Long Circulating Liposomes
19. Antibody-Mediated Targeting of PEG-Coated Liposomes
20. Small Molecule Ligands for Targeting LongCirculating Liposomes.